Sign Out
It is recommended that liver function tests should be done before initiation of Tonact-FN therapy, at 12 weeks after initiation of therapy and periodically thereafter semiannually. If the liver enzyme values exceed three times the upper normal limit, Tonact-FN must be discontinued. If cholelithiasis is suspected, or if gallstones are found, fenofibrate (in Tonact-FN) must be stopped.
Combined use of oral anticoagulants, cyclosporine and resins with fenofibrate (in Tonact-FN) should be with due precaution. Medications known to exacerbate hypertriglyceridemia (beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of fenofibrate (in Tonact-FN) therapy.
Safety and efficacy of fenofibrate and atorvastatin (in Tonact-FN) in pediatric patients have not been established. Dose of fenofibrate (in Tonact-FN) must be carefully titrated in the elderly.
